Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-ACT-101
- Development stage
- Preclinical
- Lead developer
- Alpha Cancer Technologies
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
177Lu-ACT-101 is a targeted radiopharmaceutical therapeutic being developed by Alpha Cancer Technologies for the treatment of various cancers. It consists of ACT-101, a recombinant, non-glycosylated form of human alpha-fetoprotein (AFP), labeled with the beta-emitting radioisotope lutetium-177 (177Lu). The drug targets the alpha-fetoprotein receptor (AFPR), which is highly expressed on over 80% of cancer cells—including colorectal, ovarian, breast, prostate, and lung cancers—but is minimally present on healthy adult tissues. Upon binding to the AFPR, the radiopharmaceutical is internalized, delivering localized ionizing radiation directly to the tumor cells to induce DNA damage and cell death while sparing normal tissues. It is part of a theranostic platform that includes a corresponding diagnostic imaging agent, 89Zr-ACT-101.
- Other names
- Lutetium (177Lu) ACT-101177Lu-labeled ACT-101
02
Targets
RPSA (37/67 kDa laminin receptor)
Beyond the preview
Go deeper on 177Lu-ACT-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-ACT-101.